학술논문
The impact of dupilumab treatment on SARS‐CoV‐2 T cell responses in atopic dermatitis patients.
Document Type
Article
Author
Source
Subject
*T cells
*SARS-CoV-2
*ATOPIC dermatitis
*DUPILUMAB
*MONONUCLEAR leukocytes
*THYMIC stromal lymphopoietin
*
*
*
*
*
Language
ISSN
0105-4538
Abstract
Overall, this study suggests that Th2-inhibition with dupilumab does not hinder, and may possibly even improve, Th1-specific T cell responses to COVID-19 infection and mRNA vaccination. Fifty-five samples from patients with prior SARS-CoV-2 infection confirmed by positive anti-SARS-CoV-2 Spike IgG (unvaccinated at the time of sample collection), and 125 post-vaccination samples from different subjects were analyzed. Spike antigens were used to provide comparisons between treatment groups as a measure of T cell responses for both post-infection and post-vaccination samples (the vaccine contains only spike antigen of SARS-CoV-2). [Extracted from the article]